Sanofi's Q1 even worse than feared
This article was originally published in Scrip
Sanofi has reported a first quarter even poorer than forecast, with sales down 3%. 2013 is the year Sanofi will feel worst effects of its patent cliff, particularly in the US. Analysts had expected sales to drop by around 1% (scripintelligence.com, 30 April 2013).